Search for content, post, videos

BC Platforms signs new partnership


BC Platforms has signed a partnership with Codigo46, an emerging Mexican company, focused on building and managing the largest biobank in Latin-America in co-operation with Mexican health and research specialists to deliver clinical patient benefits and future personalised medicines through academic and commercial research.

This biobank, which is unique due to the Mexican genotype which has a native American and European mix, is expected to grow to over one million genotypic and phenotypic data samples over the next three years.

BC Platforms will deliver a bespoke technology platform enabling Codigo46’s global customers and collaborators to efficiently access and analyse this data without compromising its integrity. This platform will provide automated systems and high end infrastructure to enable the acquisition of large volumes of data from new sources. Codigo46 has adopted Illumina’s recently announced  Infinium Global Screening Array (GSA).  The chip has been designed for genetic risk screening of large global populations.


Lorenza Haddad Chief Executive Officer at Codigo46, commented: “We are very excited to partner with BC Platforms. We believe that with their support and expertise we can achieve our ambitious goal to build the largest biobank in Latin America. Our ambitions are not just to generate a genetic database, but also to incorporate clinical data from hospital systems with patient consent and be a part of different research projects. It will be the first biobank to provide such extensive data sets from subjects of this diverse genotype and we expect it will be a highly valuable resource for academic and commercial research across the globe.”

Tero Silvola, Chief Executive Officer at BC Platforms, commented: “We feel privileged to collaborate with Codigo46 on this unique project and support the translation of these diverse samples into valuable data for academic and commercial research. We are excited to work in partnership to develop a bespoke technology platform to support them in their mission to build the largest biobank in Latin America.”